Using the latest technologies including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize ke
Published: Dec 14, 2020
SAN FRANCISCO, Dec. 14, 2020 /PRNewswire/ Astellas Venture Management (President: Kazunori Maruyama, Ph.D, AVM ), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs ( MBC BioLabs ), a life-science incubator, today announced
Keyhole Therapeutics, Inc. and
Jupiter Therapeutics, Inc. as the winners of their
Golden Ticket Competition . Building on the success of the inaugural competition held in 2019, the award supports entrepreneurial scientists and emerging biotechnology start-ups to accelerate early drug discovery and innovation for the potential future benefit of patients worldwide.
Entries were received across a broad range of disease areas and exciting innovative technologies from which the winning companies were identified. Keyhole Therapeutics and Jupiter Therapeutics were chosen for the potential of their innovations to deliver therapeutic advances for unmet medical needs and their pot